AbbVie, perusahaan biopharmaceutical global adhedhasar riset, ngumumake Health Canada wis nyetujoni SKYRIZI® (risankizumab), kanggo perawatan pasien diwasa kanthi arthritis psoriatik aktif. Ing PsA, SKYRIZI bisa digunakake piyambak utawa dikombinasikake karo obat antireumatik non-biologis konvensional (cDMARD) (contone, methotrexate).
"SKYRIZI nampa Kabar Kepatuhan kanggo perawatan arthritis psoriatik aktif menehi pangarep-arep tambahan kanggo pasien. Asil saka program uji klinis Fase 3 nuduhake perbaikan ing tandha-tandha lan gejala sing ana gandhengane karo penyakit iki, "ujare Dr. Kim Alexander Papp, MD, PhD, FRCPC, FAAD, Probity Medical Research.
"Ing AbbVie, kita ngupayakake kanggo ngowahi standar perawatan kanggo wong immunocompromised, lan kita bungah karo persetujuan Health Canada saka SKYRIZI kanggo perawatan wong diwasa karo atritis psoriatic aktif," ngandika Tracey Ramsay, Wakil Presiden lan General Manager, AbbVie Canada.
Iki minangka indikasi kapindho kanggo SKYRIZI ing Kanada. Ing April 2019, Health Canada nyetujoni SKYRIZI kanggo perawatan pasien diwasa kanthi psoriasis plak moderat nganti abot sing dadi calon terapi sistemik utawa fototerapi.
APA sing kudu dijupuk saka ARTIKEL INI:
- “At AbbVie, we strive to transform the standard of care for immunocompromised people, and we are excited with Health Canada’s approval of SKYRIZI for the treatment of adults with active psoriatic arthritis,”.
- In April 2019, Health Canada approved SKYRIZI for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- In PsA, SKYRIZI can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.
